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Introduction
Type 1 diabetes (T1D) is a consequence of  autoimmune destruction of  β cells, involving activation 
of  cellular immunity and inflammation initiated by early-stage immune cell infiltration of  islets (1). 
While the roles of  various stressors (i.e., cytokines, ROS, glucose) in this process have been studied 
extensively, the impact of  lipids on β cell health during T1D development has not received significant 
attention. As such, there exists a significant gap in the understanding of  how lipids generated by 
immune cells and/or β cells contribute to β cell demise.
Phospholipases A2 (PLA2s) hydrolyze the sn-2 substituent of  glycerophospholipids to release a lys-
ophospholipid and a free fatty acid (2). When the fatty acid is arachidonic acid, it can be metabolized 
by cyclooxygenases (COX), lipoxygenases (LOX), and cytochrome P450 (CYP) enzymes to generate 
oxidized bioactive lipids, or eicosanoids, which manifest a variety of  effects. Some of  the most potent 
inflammatory eicosanoids (3) are prostaglandin E2 (PGE2), leukotrienes (LTs), HETEs, and dihydroxye-
icosatrienoic acids (DHETs), and they contribute to autoimmune diseases (4).
Among the PLA2s is a Ca
2+-independent phospholipase A2 (iPLA2β), and its activity promotes deleteri-
ous outcomes in experimental and clinical diabetes (5, 6). Immune cells express iPLA2β (7), and inhibition 
of  iPLA2β reduces generation of  ROS (7), as well as antibody production from B cells and TNF-α from 
Type 1 diabetes (T1D) is a consequence of autoimmune β cell destruction, but the role of lipids in 
this process is unknown. We previously reported that activation of Ca2+-independent phospholipase 
A2β (iPLA2β) modulates polarization of macrophages (MΦ). Hydrolysis of the sn-2 substituent 
of glycerophospholipids by iPLA2β can lead to the generation of oxidized lipids (eicosanoids), 
pro- and antiinflammatory, which can initiate and amplify immune responses triggering β cell 
death. As MΦ are early triggers of immune responses in islets, we examined the impact of iPLA2β-
derived lipids (iDLs) in spontaneous-T1D prone nonobese diabetic mice (NOD), in the context 
of MΦ production and plasma abundances of eicosanoids and sphingolipids. We find that (a) 
MΦNOD exhibit a proinflammatory lipid landscape during the prediabetic phase; (b) early inhibition 
or genetic reduction of iPLA2β reduces production of select proinflammatory lipids, promotes 
antiinflammatory MΦ phenotype, and reduces T1D incidence; (c) such lipid changes are reflected 
in NOD plasma during the prediabetic phase and at T1D onset; and (d) importantly, similar lipid 
signatures are evidenced in plasma of human subjects at high risk for developing T1D. These 
findings suggest that iDLs contribute to T1D onset and identify select lipids that could be targeted 
for therapeutics and, in conjunction with autoantibodies, serve as early biomarkers of pre-T1D.
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CD4+ T cells (8) and macrophages (MΦ) (9). Inhibition of  iPLA2β has been shown to be effective in coun-
tering autoimmunity (10) and inflammation (11). Islet-resident MΦ and early islet-infiltrating MΦ promote 
infiltration of  other immune cells, with M1 proinflammatory MΦ (12) recognized as causative factors in 
T1D development (13), whereas M2 antiinflammatory MΦ (14) are protective against T1D (15).
We and others have demonstrated that iPLA2β participates in β cell apoptosis (16, 17) and modu-
lates MΦ polarization (18, 19). In light of  these observations, we herein used lipidomics to gain insight 
into the lipidome associated with T1D development in NOD mice (hereafter referred to as NOD) and 
humans at high risk for developing T1D.
Results
Nomenclature
Mice used in these studies included spontaneous diabetes–resistant C57BL/6J, spontaneous diabetes–
prone NOD, and NOD.PLA2G6+/–. These strains are designated C57, NOD, and NOD-HET, respectively. 
MΦ from these are designated MΦC57, MΦNOD, and MΦNOD-HET, respectively.
Age-dependent impact of iPLA2β inhibition on T1D development
As the female NOD exhibit a recognized progression in T1D development (1), where onset of  insulitis 
commences at about 4 weeks of  age and the inflammatory processes ramp up at about 8 weeks of  age, we 
monitored T1D development in female NOD administered FKGK18 starting at 10 days and 4 or 8 weeks 
of  age. Similar to our earlier report (8), 80%–90% of  vehicle-treated NOD became diabetic by 25–30 weeks 
of  age in the 10-day group, but only 10%–15% NOD administered FKGK18 developed T1D (data not 
shown). The vehicle-treated (PBS-T–treated) groups in the 4-week (Figure 1A) and 8-week (Figure 1B) 
groups also exhibited an 80% T1D incidence by 25–30 weeks of  age. In contrast, 40% of  mice in the 4-week 
FKGK18 group remained diabetes free (Figure 1A). While there was evidence of  a modest delay in T1D 
incidence in the 8-week FKGK18 group (Figure 1B), it was not significantly different from the correspond-
ing PBS-T group. No differences in glucose tolerance were noted between the groups started on PBS-T and 
FKGK18 at either 4 weeks (Figure 1, C and D) or 8 weeks of  age (Figure 1, E and F).
Because the 8-week FKGK18-treated group appeared to be at the cusp of  effective iPLA2β intervention, 
we further probed β cell and islet immune cell phenotype in this group. As expected, FKGK18 administra-
tion reduced urinary PGE2 metabolites (PGEM, Figure 1G), relative to the vehicle-treated mice, reflecting 
in vivo FKGK18-mediated inhibition of  iPLA2β activity. This was accompanied by similar β cell mass (Fig-
ure 1H), higher circulating insulin (Figure 1I), and reduced islet infiltration (Figure 1, J and K). Further-
more, pancreatic islet abundances of  CD4+ T cells (Figure 1L) and B cells (Figure 1M) were significantly 
reduced in the FKGK18-treated mice, relative to the PBS-T group. These findings reveal an age-dependent 
impact of  iPLA2β inhibition on T1D, with early intervention being more beneficial.
Protective effects of iPLA2β inhibition are lost upon FKGK18 withdrawal
To determine if the protective effects of early intervention persist following inhibitor withdrawal, a concurrent 
cohort NOD group administered FKGK18 from 10 days until 14 weeks of age, an age closely associated with 
onset of T1D (20), was monitored for up to 30 weeks. We find that the decreased incidence in the NOD treat-
ed with FKGK18 continuously from 10 days until 30 weeks of age (8) was not evident when FKGK18 was 
withdrawn after 14 weeks (Figure 2A). Glucose tolerance was also indistinguishable between the PBS-T– and 
FKGK18-withdrawn groups (Figure 2, B–E). Taken together, these findings suggest that the protective effects 
of the reversible inhibitor FKGK18 are lost upon withdrawal.
MΦNOD exhibit a profound inflammatory lipid profile
In view of  the above observations suggesting a temporal impact of  iPLA2β-derived lipids (iDL) on T1D 
development, we examined the lipid profile in the NOD, as compared with C57. MΦ are key to the auto-
immune-mediated destruction of  β cells, leading to T1D, as they are among the first cells to infiltrate the 
islets and trigger processes that promote infiltration of  other immune cells (21, 22). Our earlier assessments 
of  specific phenotypic markers revealed that iPLA2β activation promotes MΦ polarization toward M1, 
whereas iPLA2β deficiency favors M2 antiinflammatory polarization (18). We therefore targeted the MΦ 
lipid profile for analyses in the studies here. Peritoneal MΦ were isolated from mice and treated with either 
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Figure 1. Effects of temporal FKGK18 regimen on T1D incidence and islet phenotype. Female NOD mice were administered FKGK18 (20 mg/kg, 3 × weekly) 
or vehicle (PBS-T) starting at 4 or 8 weeks of age. (A and B) Diabetes incidence. Blood glucose was monitored weekly in the 4-week (A; n = 17 and 15 for 
PBS-T and FKGK18 groups, respectively) and 8-week (B; n = 15 each in the PBS-T and FKGK18 groups) regimen groups for up to 30 weeks. Two consecutive 
readings of ≥ 275 mg/dL were recorded as onset of T1D (†P < 0.05). (C–F) Glucose tolerance test (GTT). Overnight fasted mice were administered glucose 
(2 g/kg, i.p.), glucose levels in blood from tail vein were monitored over a 2-hour period, and AUC were generated. (C and D) Four-week group at 14 weeks 
of age; n = 5 each in the PBS-T and FKGK18 groups. (E and F) Eight-week group at 25 weeks of age; n = 7 and 5 for PBS-T and FKGK18 groups, respectively. 
(G–I) Phenotype parameters in the 8-week regimen group. (G) Urinary PGE2 metabolites (PGEMs, n = 6 in each group, 18 weeks of age). (H and I) β Cell 
mass (PBS-T, n = 15; FKGK18, n = 14) (H) and circulating insulin (n = 15 in each group) (I) were determined at sacrifice (PBS-T, 14–30 weeks of age; FKGK18, 
16–36 weeks of age). (J and K) Islet infiltration. Paraffin sections (10 μm) of pancreas were prepared and stained with H&E. Percent infiltration for each 
islet was calculated as the value of noninfiltrated area subtracted from total islet area (% infiltrate = 100 × [(total area – noninfiltrated area)/(total area)]) 
using ImageJ software. (PBS-T, n = 14 and 166 islets; FKGK18, n = 15 and 260 islets). (J) Islet Infiltration Range. (K) Average islet infiltration. (L and M) Islet 
immune cell phenotype. Paraffin sections (10 μm) of pancreas were prepared and stained for CD4+-T cells or B (B220) cells. Data presented are mean ± SEM 
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vehicle control (DMSO) or activated with IFN-γ + LPS. The media was collected for lipidomics analyses 
of  eicosanoids, specialized proresolving mediators (SPMs), and fatty acids and the cells for sphingolip-
ids. Multiple reaction monitoring (MRM) transitions with corresponding declustering potentials, collision 
energies, entrance potentials, and collision cell exit potentials are shown in Supplemental Tables 1 and 2 
(supplemental material available online with this article; https://doi.org/10.1172/jci.insight.138034DS1).
Eicosanoids and fatty acids. Metabolites of  arachidonic acid are recognized to be pro- or antiinflammatory. 
In comparison with MΦC57, production of  several proinflammatory prostaglandins (PGs) by MΦNOD was sig-
nificantly higher under both basal and activated conditions (Supplemental Table 3A). The most profoundly 
affected lipids included 6-keto PGF1α, 8-Iso PGF2α, 5-IPFα-VI, PGE2, PGA2, and 15-deoxy-Δ12,14-PGJ2. 
Furthermore, LT (LTD4, LTC4, and LTE4) production by MΦC57 was significantly increased under basal 
conditions, and LTD4 production remained higher under activating conditions, in comparison with produc-
tion by MC57. Production of  HETEs, DHETs, or PGE1 was not significantly different between the 2 groups 
under basal conditions, but under activating conditions, production of  12-HETE, (±) 8,9-DHET, and PGE1 
by MΦNOD was significantly higher, relative to MΦC57 (Supplemental Table 3, A and B). Cellular lipidomic 
analyses identified several SPMs, including resolvin D2 and D1 (from docosahexaenoic acid [DHA]), and 
lipoxin A4 (from arachidonic acid [AA]). However, production of  these or fatty acids EPA, DHA, and AA 
(Supplemental Table 3C) by MΦNOD and MΦC57 was not different under basal or activated conditions.
Sphingolipids. As our earlier studies revealed that stress-induced β cell death is associated with increases 
in various proapoptotic ceramides (CMs) (17, 23, 24), we assessed sphingolipids production by MΦNOD. 
We found that several CM species (C16:0, C22:0, C24:1, C24:0) are higher in MΦNOD under both basal and 
classical activation, relative to MΦC57 (Supplemental Figure 1, A and B). Some monohexyl CM (MHCM) 
species are decreased in MNOD, relative to MΦC57 — in particular, C16:0-MHCM (Supplemental Figure 1, C 
and D). Several sphingomyelin (SM) species (C18:1, C18:0, C20:0, C22:0, and C24:1) were elevated under 
basal conditions, with the 16:0 species decreasing in the MΦNOD, relative to MΦC57 (Supplemental Figure 
1, E and F). The only significant difference under classical activation was an increase in the C24:1-SM 
in MΦNOD, relative to MΦC57. Among the CM-1–phosophate (C1P) species, C22:0 was lower and C24:0 
higher under basal conditions and 16:0 higher under classical activation in MΦNOD, relative to MΦC57 (Sup-
plemental Figure 1, G and H). Although little is known as to the chain length specificity of  C1P in driving 
inflammatory responses, the C16:0 species is usually associated with inflammatory responses, induction of  
inflammatory eicosanoid biosynthesis, and MΦ migration (25).
Collectively, these findings suggest that the spontaneous diabetes–prone NOD is inherently in a height-
ened inflammatory state, as reflected by the higher abundances of  proinflammatory lipids and higher 
iPLA2β mRNA (C57, 1.00 ± 0.07; NOD, 1.83 ± 0.05, P < 0.001, n = 3/group).
Reduction in iPLA2β expression in NOD mitigates T1D parameters and favors M2-MΦ 
phenotype
As the elevated lipids in MΦNOD can be generated in an iPLA2β-dependent manner, we examined the 
consequences of  reduced iPLA2β expression on T1D development by comparing NOD and NOD-HET 
littermates. Genotype was verified by PCR analyses (Figure 3A), which generated the expected product 
sizes of  1400 bp for NOD and 1400 bp and 400 bp for NOD-HET. Blood glucose monitoring revealed 
approximately 75% T1D incidence in NOD (Figure 3B). In contrast, approximately 80% of  the NOD-
HET remained diabetes free, and this was accompanied by reduced iPLA2β (~65%) (Figure 3C) and 
TNF-α production by CD4+ T cells (Figure 3D) and higher M2 marker, Arg1 (Figure 3E), relative to 
NOD. Furthermore, insulitis was reduced in the NOD-HET (20%–24%) relative to NOD (49%–56%). 
These findings support a link between iPLA2β, MΦNOD polarization, and T1D development, raising the 
importance of  identifying the iDLs contributing to T1D development.
Reduced iPLA2β expression mitigates MΦNOD production of select proinflammatory lipids
Eicosanoids and SPMs. In view of  the above observations, we predicted that decreased iPLA2β expression 
would mitigate production of  proinflammatory lipids by MΦ between 4 and 8 weeks of  age. Produc-
tion of  lipids by MΦNOD and MΦNOD-HET under classical activation was not significantly different at 
of CD4+ T cells or B cells per islet. (L) Quantitation of CD4± T cells per islet (PBS-T, n = 14 and 223 islets; FKGK18, n = 15 and 290 islets). (M) Quantitation of B 
cells per islet (PBS-T, n = 14 and 213 islets; FKGK18, n = 15 and 328 islets). Statistical analyses: (A and B) Mantel-Cox test; (D–M) Student’s t test.
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4 weeks of  age (Figure 4), with the exception of  8-Iso PGF2α, which was higher from MΦNOD, rel-
ative to MΦNOD-HET. Between 4 and 8 weeks of  age, classical activation resulted in lower production 
of  several proinflammatory lipids (6-keto PGF1α, 8-Iso PGF2α, PGE2, PGA2, total proinflammato-
ry pool, and 20-HETE) by MΦNOD-HET (Figure 4, A–F), relative to MΦNOD. However, production of  
proinflammatory 5-HETE by MΦNOD-HET was higher (Figure 4G) and antiinflammatory was PGE1 
lower (Figure 4H), relative to production by MΦNOD. Interestingly by 14 weeks of  age, the produc-
tion of  eicosanoids by MΦNOD and MΦNOD-HET was dramatically reduced, but production of  several 
of  the same proinflammatory PGs, LTE4, (±) 8,9-DHET, and 15-HETE by MΦNOD remained signifi-
cantly higher, relative to MΦNOD-HET (Figure 4I). Moreover, production of  PGE1 by MΦNOD continued 
to be higher, relative to MΦNOD-HET (Figure 4J; absolute fold increases from independent measures of  
select lipids are presented in Supplemental Figure 2). All other eicosanoids, SPMs, and fatty acids 
were not significantly affected between 4 and 14 weeks (Supplemental Table 4, A and B). These find-
ings reveal that production of  select proinflammatory eicosanoids is modulated by iPLA2β in an age- 
dependent manner, before the development of  hyperglycemia (Supplemental Figure 3).
Sphingolipids. Though classical activation induced changes in the various sphingolipid classes, 
there were no significant differences in the total pools of  CMs, monohexosyl CMs, SMs, CM-1Ps, or 
sphingosines between MΦNOD and MΦNOD-HET (Supplemental Table 4C). These findings suggest that 
iPLA2β-mediated sphingolipid production by MΦ during the prediabetic phase may not be important 
contributors to T1D development.
Select plasma lipid changes are associated with iPLA2β inhibition or expression
NOD versus NOD-HET. To determine if  inhibition of  iDL production can also be evidenced in circulating 
levels of  lipids, we assessed plasma lipidome of  NOD and NOD-HET through 14 weeks of  age (predi-
abetic phase). At 4 and 8 weeks of  age, no significant differences in eicosanoids, sphingolipids, or fatty 
acids were noted between the NOD and NOD-HET (data not shown). At 14 weeks of  age, proinflam-
matory DHET abundance was low but higher in the NOD-HET, relative to NOD (Figure 5A). Among 
the proinflammatory LTs, LTC4 was reduced 2.6-fold, its precursor LTE4 increased 2-fold, and LTB4 
Figure 2. Effects of FKGK18-withdrawal regimen 
on T1D incidence and glucose tolerance. Female 
NOD mice were administered FKGK18 (20 mg/kg, 
3 × weekly, n = 18) or vehicle (PBS-T, n = 17) start-
ing at 10 days of age and until 14 weeks of age. 
(A) T1D incidence. Blood glucose was monitored 
weekly for up to 30 weeks, and 2 consecutive 
readings of ≥ 275 mg/dL were recorded as onset 
of T1D. (B and D) Glucose tolerance test (GTT). 
Assessed at 14 (B) and 25 (D) weeks of age (data 
are presented as mean ± SEM), as described in 
Figure 1. (C and E) Corresponding AUC. N values 
for PBS-T & FKGK18: 8 and 8 (B and C); , 8 and 6 
(D and E), respectively. Statistical analyses: (A) 
Mantel-Cox test; (C and E) Student’s t test.
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was absent in NOD-HET, relative to NOD (Figure 5B). In contrast, the abundance of  antiinflammatory 
epoxyeicosatrienoic acids (EETs) were greater and significantly higher in the NOD-HET, relative to 
NOD (Figure 5C). Moreover, the abundance of  EPA and di-homo-γ-linolenic acid (DHGLA) was high-
er in NOD-HET by 14 weeks of  age, as compared with NOD (Figure 5D). Furthermore, the ratios of  
phosphorylated to nonphosphorylated sphingosine (So1P/So) and sphinganine (Sa1P/Sa) were lower in 
the NOD-HET by 14 weeks of  age, relative to NOD (Figure 5E). Analyses of  plasma CM sphingolipids 
revealed a select increase in CM C16:0 in NOD-HET, relative to NOD at 14 weeks of  age (Figure 5F). 
However, multiple monohexosyl CMs (Figure 5G), SMs (Figure 5H), and CM-1Ps (Figure 5I), including 
the C16:0 species, were increased in the NOD-HET, relative to NOD.
Next, to determine if  a proinflammatory landscape persists until T1D onset, we performed lipid-
omic analyses with plasma from FKGK18- and PBS-T–treated NOD (starting at 10 days). The analyses 
comparing PBS-T–treated NOD that did not become diabetic (P [nd]), vehicle-treated NOD that became 
diabetic (P [d]), and FKGK18-treated (from 10 days of  age) NOD that did not turn diabetic (FK [nd]) 
revealed significantly greater abundance of  proinflammatory LTC4, 15-HETE, 5-HETE, PGD2, and AA 
in the plasma from diabetic PBS-T–NOD, in comparison with nondiabetic PBS-T– or FKGK18–treated 
NOD (Figure 6, A–E, respectively). Furthermore, the ratio of  So1P/So was higher in diabetic PBS-T–
NOD, in comparison with nondiabetic PBS-T– or FKGK18-treated NOD (Figure 6F). In contrast, the 
ratio of  antiinflammatory EET to proinflammatory DHET pools was reduced in diabetic PBS-T–NOD, 
in comparison with nondiabetic PBS-T– or FKGK18-treated NOD (Figure 6G). Surprisingly, SPM resol-
vin D2 (Figure 6H) and its fatty acid source DHA (Figure 6I) were significantly higher in the diabetic 
group, in comparison with either nondiabetic group. Comparison of  PBS-T– and FKGK18–treated mice 
Figure 3. NOD.iPLA2β+/– genotype and diabetes phenotype. (A) Genotype. DNA was generated from tail clips and progeny were genotyped by PCR analyses. 
Reactions were performed in the presence of primers for the WT sequence (NOD) or for the disrupted sequence (NOD-HET) for each mouse. The expected 
bands for the WT (1400 bp) and HET (1400 and 400 bp) in 2 mice each are presented. L, bp ladder. (B) T1D incidence. Blood glucose was monitored weekly 
for up to 30 weeks, and 2 consecutive readings of ≥ 275 mg/dL were recorded as onset of diabetes (n = 12 and 17 for NOD and NOD-HET groups, respective-
ly). NOD-HET significantly different from NOD; ¥P < 0.001. (C) RNA was isolated from NOD (n = 3) and NOD-HET (n = 3) macrophages and cDNA prepared for 
iPLA2β mRNA analyses by qPCR. (D) Production of TNF-α by CD4+ T cells. Splenocytes were prepared from the NOD and NOD-HET, and CD4+ T cells were isolat-
ed and activated, as described in Methods. The media was collected at 72 hours, and TNF-α concentration was determined by ELISA (n = 3 per group). (E) RNA 
was isolated from NOD (n = 3) and NOD-HET (n = 3) macrophages and cDNA prepared for Arg1. Statistical analyses: (B) Mantel-Cox test; (C–E) Student’s t test.
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that developed T1D revealed no differences between the two groups (initiated at 10 days or 4 weeks of  
age), with the exception of  a decrease in PGD2 in the FKGK18 group, relative to the PBS-T (d) groups 
(Supplemental Figure 4). Collectively, these analyses reveal select changes in iPLA2β-dependent plasma 
lipid profiles that may be important indicators of  T1D development.
Adoptive transfer of peritoneal iPLA2β-deficient MΦ reduces T1D incidence
Adoptive transfer of  M2-MΦNOD has been reported to reduce T1D incidence in the NOD (15). Using an 
analogous approach, we performed an adoptive transfer study using peritoneal MΦ isolated from NOD 
Figure 4. Comparison of eicosanoid production by MΦNOD and MΦNOD-HET. Peritoneal MΦ isolated from female NOD and NOD-HET mice were treated with 
vehicle control (DMSO) or classically activated with IFN-γ + LPS, and the media was collected for eicosanoid analyses at 16 hours. The data (estimated 
marginal mean ± SEM) represent fold-change in activated lipids, relative to corresponding control. MΦNOD (n = 9 and 5) and MΦNOD-HET (n = 4 and 3) at 4 and 
8 weeks, respectively. (A) 6-Keto PGF1α. (B) 8-Iso PGF2α. (C) PGE2. (D) PGA2. (E) Proinflammatory prostaglandin (PG) pool. (F) 20-HETE. (G) 5-HETE. (H) 
PGE1. (I and J) Proinflammatory (I) and antiinflammatory PGE1 (J) at 14 weeks. NOD-HET significantly different from NOD, †P < 0.05; δP < 0.01; #P < 0.005; 
¥P < 0.001, n = 9 in each group. Statistical analyses: (A–H) multivariate 2-way ANOVA and time-course ANOVA; (I and J) Student’s t test.
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and NOD.iPLA2β
–/– (KO) mice, rationalizing that the KO MΦ are analogous to M2-MΦ. We found 
that T1D incidence in NOD administered the KO MΦ was significantly reduced, relative to the mice 
administered NOD MΦ (Supplemental Figure 5). These studies support the ability of  peritoneal MΦ to 
infiltrate the islets and participate in the pathogenic process of  T1D and support the idea that this can 
be mitigated when MΦ-iPLA2β is reduced.
Plasma lipidome of subjects at high risk for developing T1D
To determine if  a similar lipid signature is evident in human subjects at high risk for developing T1D, plas-
ma samples from nondiabetic (normoglycemic) autoantibody negative (Aab–), one Aab-positive (Aab+), or 
2 Aab-positive (Aab++) and recent-onset (RO, TID duration < 3.4 months) subjects were processed for lipid-
omics analyses (Figure 7). The subjects were a mixture of  male and female children, between 9 and 15 years 
old, where no significant differences in prevalence between the sexes are reported (26–28). These assessments 
identified increases in PGE2, PGD2, PGA2, 15-HETE, and LTE4, and a decrease in precursor LTC4, in the 
Figure 5. Comparison of select plasma lipids during the prediabetic phase. (A–I) Plasma was prepared from NOD (n = 5) and NOD-HET (n = 5) and pro-
cessed for lipidomics analyses of eicosanoids (A–C), fatty acids (D), and sphingolipids (E–I). The data (mean ± SEM) represent pmol of each lipid species 
in 100 μL (A–D) or 50 μL (E–I) plasma. (A) DHETs. (B) Leukotrienes. (C) EETs. (D) EPA and DHGLA. (E) Sphingosine and sphinganine (phosphorylated/non-
phosphorylated). (F) Ceramides. (G) Monohexosyl Ceramides. (H) Sphingomyelins. (I) Ceramide-1-phosphates. NOD-HET significantly different from NOD, 
†P < 0.05; δP < 0.01; #P < 0.005; πP < 0.0005. Statistical analyses: Student’s t test. UD, undetected.
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Aab++ group that were significant (P < 0.05) or approached significance (Figure 7, A–F), as reflected by 
Pearson, Kendall, and Spearman rank order correlation analyses (Table 1). Notably, differences recorded in 
the Aab++ subjects occurred in the absence of  hyperglycemia (Figure 7G). Of import, these select proinflam-
matory eicosanoids exhibited a similar step-wise profile: Aab– < Aab+ < Aab++, with the RO group trending 
back to Aab– levels. Taken together with the observations in the NOD models, these findings are consistent 
with a heightened select proinflammatory iDLs landscape in human subjects at high risk for developing T1D.
Discussion
MΦ are among the first to infiltrate islets and initiate the sequelae of  events that cause β cell destruction, 
and evidence points to involvement of  signals generated by immune cells and islets in amplifying the 
immune responses (29). Very little is known about the contribution of  lipid signaling toward β cell death 
in T1D. We find that, in comparison of  spontaneous T1D-prone (NOD) and spontaneous T1D-resistant 
(C57) mice, MΦNOD produce significantly higher proinflammatory eicosanoids and sphingolipids under 
both basal and activated conditions. To date, these are the first demonstrations to our knowledge of  a 
Figure 6. Comparison of select plasma lipids at T1D onset. NOD mice were treated with PBS-T or with FKGK18, starting at 10 days of age, and sacrificed 
at the onset of T1D (d) or at 30 weeks if they remained nondiabetic (nd). Plasma was prepared from these mice and processed for lipidomics analyses. The 
data (mean ± SEM) represent pmol of each lipid species in 100 or 50 μL plasma. (A) LTC4. (B) 15-HETE. (C) 5-HETE. (D) PGD2. (E) AA. (F) So1P/So. (G) EET/
DHET. (H) Resolvin D2. (I) DHA. n = 3, 4, and 4 for PBS-T (P [nd]), PBS-T (P [d]), and FKGK18 (FK [nd]), respectively. P (d) significantly different from the 
other groups, †P < 0.05; δP < 0.01; ΔP < 0.000001. One-way ANOVA.
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heightened proinflammatory lipid profile in NOD, which would be expected to confer an inherent suscep-
tibility of  the NOD to inflammation-mediated responses associated with T1D development.
iPLA2β has been reported to participate in a variety of  biological processes and contribute to the onset 
and/or progression of  inflammatory disorders (30). Therefore, development of  inhibitors of  iPLA2β has 
Figure 7. Diabetic and nondiabetic human plasma lipidome. Lipidomics analyses were per-
formed in plasma from euglycemic autoantibody negative (Aab–), 1 Aab-positive (Aab+), and 2 
Aab-positive (Aab++), and recent T1D onset (3.34 ± 0.24 months T1D duration) (RO) subjects. The 
number of subjects, sex (female [F]/male [M]) distribution, and age (years) at visit are: Aab–, 10, 
2F/8M, 9.26 ± 1.68; Aab+, 11, 6F/5M, 14.60 ± 1.38; Aab++, 11, 8F/3M, 12.43 ± 1.66; RO, 13, 9F/4M, 
8.99 ± 1.33. (A–F) Fold-abundances in lipids, relative to Aab–, are presented with mean ± SEM. (G) 
Blood glucose at sample collection. Statistical analyses: (A–F) Pearson, Kendall, and Spearman’s 
rank order correlation; G, Student’s t test. All n is the same as previous panels, except RO = 12.
Table 1. Statistical analyses of human T1D lipidome
Pearson’s R Kendall’s Tau Spearman’s Rho
Lipid Correlation Sig. Correlation Sig. Correlation Sig.
PGE2 0.337 0.059 0.260 0.064 0.337 0.059
PGD2 0.306 0.089 0.241 0.087 0.304 0.090
PGA2 0.440 0.012 0.338 0.016 0.425 0.015
15-HETE 0.423 0.016 0.294 0.037 0.351 0.049
LTC4 –0.397 0.025 –0.300 0.033 –0.372 0.036
LTE4 0.510 0.062 0.481 0.055 0.533 0.050
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been pursued to counter its deleterious effects. Earlier inhibitors of  iPLA2β included arachidonyl trifluo-
romethyl ketone (ATFMK) and bromoenol lactone (BEL); while ATFMK has been shown to also inhibit 
cytosolic PLA2 (cPLA2) (31, 32), BEL has been reported to inhibit a variety of  enzymes with active site 
cysteine residues (33). This prompted efforts to develop more selective inhibitors of  iPLA2β and led to 
the initial identification of  FKGK11 (1,1,1,2,2-pentafluoro-7-phenylheptan-3-one) (34). Continued struc-
ture-activity relationship analyses revealed that a trifluoromethyl ketone compound, FKGK18, exhibited 
much greater selectivity and potency toward iPLA2 than cPLA2 or secretory PLA2 (sPLA2) (35). Subse-
quently, we demonstrated that FKGK18 was a reversible inhibitor with greater selectivity for iPLA2β than 
iPLA2γ. Furthermore, FKGK18 was found to be effective in inhibiting ER stress–induced β cell apopto-
sis, without apparent nonspecific protease activity (36). Our body of  previous work suggested a role for 
iPLA2β in β cell apoptosis, which leads to T1D development; we therefore considered the possibility that 
iPLA2β inhibition with FKGK18 might lead to mitigation of  T1D incidence. Guided by an earlier report 
demonstrating beneficial effects of  FKGK11 in experimental autoimmune encephalomyelitis (EAE) 
(10), we investigated the effects of  FKGK18 in the spontaneous T1D–prone NOD mouse. We found that 
FKGK18 administration to NOD starting at 10 days of  age ameliorated insulitis and T1D incidence, with-
out promoting nonspecific cytotoxic effects (8). These findings motivated us to use FKGK18 to further 
investigate the temporal impact of  iPLA2β on T1D development.
From the studies here, we were able to glean that iPLA2β inhibition starting at 4 weeks (age of  insu-
litis onset), but not at 8 weeks (heightened inflammation), reduced NOD diabetes incidence. However, 
the 8-week regimen promoted some beneficial endotypes, although they were muted in comparison with 
neonatal inhibition (8). No beneficial outcomes were evident on T1D incidence when FKGK18 was with-
drawn at 14 weeks of  age (initiated at 10 days). These data stand in contrast to the continued protection 
against development of  symptoms associated with EAE following withdrawal of  FKGK11 (10). This rais-
es the possibility that the presence of  persistent stressors in spontaneous models of  autoimmune disease 
makes the mice more susceptible to treatment withdrawal, in comparison with an induced EAE model. 
Consistently, we find that continual iPLA2β inhibition (8) or genetic iPLA2β reduction was effective in dra-
matic and equivalent amelioration in T1D. These findings led us to posit that the impact of  iDLs on T1D 
development is in the prediabetic phase and provided motivation to pursue expanded lipidomics analyses in 
genetically modified NOD, thus precluding potential nonspecific effects of  chemical inhibitors.
We subsequently generated NOD with reduced expression of  iPLA2β (NOD.iPLA2β
+/– or NOD-HET) 
and sought to determine if  there was a correlation between iPLA2β expression, MΦNOD lipidome, and the 
course of  T1D development. At 4 weeks of  age, activated production of  various eicosanoids and sphin-
golipids by MΦNOD and MΦNOD-HET was similar. Sphingolipid production remained similar between the 2 
groups through 14 weeks of  age, suggesting a lesser impact of  iPLA2β in MΦ sphingolipid metabolism. In 
contrast, by 8 weeks of  age, production of  select proinflammatory PGs (8-iso PGF2α, PGE2, PGA2, proin-
flammatory PG pool) and HETEs (20-HETE and 5-HETE) by MΦNOD was significantly higher than by 
MΦNOD-HET. This is consistent with the higher iPLA2β expression in prediabetic MΦNOD and the predomi-
nant antiinflammatory M2 phenotype of  MNOD-HET. The select, and not universal, changes in the lipidome 
highlights the potential impact of  these iDLs during the prediabetic phase, when ER stress and cytokines, 
known inducers of  iPLA2β (37), are ramped up in the NOD (38, 39). At 14 weeks, corresponding to the 
age approaching T1D onset, lipid production by both MΦNOD and MΦNOD-HET was dramatically reduced. 
However, production of  several proinflammatory lipids by MΦNOD remained higher than by MΦNOD-HET. 
Surprisingly, production of  antiinflammatory PGE1 from DHGLA by MΦNOD continued to be higher 
than by MΦNOD-HET, likely reflecting attempts at resolution and the dramatic drop from 8 weeks of  age, 
a failure to overcome the burden of  inflammation. Taken together, with the loss of  protective effects of  
FKGK18 following its withdrawal, these findings support the presence of  persistent stressors in sponta-
neous models of  autoimmune disease, which renders them more susceptible to treatment withdrawal. In 
the presence of  iPLA2β-dependent changes in MΦNOD lipidome during T1D development, we considered 
the possibility that this may also be reflected in the plasma. Assessment of  plasma lipidome during the 
prediabetic phase revealed no differences at 4 and 8 weeks of  age. However, significant differences in select 
lipids were noted by 14 weeks of  age. These included lower DHETs but greater decreases in EETs, higher 
LTC4 (activates NOX4 and induces ROS production) (40) with a corresponding decrease in its precursor 
LTE4 (inflammatory through GPR99) (41), and detection of  LTB4 (potent chemoattractant and induces 
ROS) in the NOD-WT, relative to NOD-HET. The EETs are generated via CYP-catalyzed metabolism of  
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arachidonic acid and have antiinflammatory properties (42). However, they can be converted by soluble 
epoxide hydrolase (sEH1) to DHETs, which are proinflammatory, and the present findings suggest that 
sEH1 is induced in the NOD, causing a decrease in the EET/DHET ratio. Among the sphingolipids, C16:0 
CM was significantly elevated in the plasma of  NOD-HET; however, this was associated with increases in 
the MHCM-C16:0 (and C18:0) and C1P-C16:0. Several species of  SMs (C18:1, C18:2, C20:0) and C1Ps 
(C22:0, C24:1, C24:0) were also higher in the NOD-HET. CMs are considered to be proapoptotic (43); 
however, their toxicity may be reduced by conversion to monohexosyl CMs, CM-1-phosphates, or SMs. 
Our findings therefore suggest that reduced expression of  iPLA2β favors sphingolipid biosynthesis toward 
species that favor cell survival and that this is reflected in plasma abundances. Furthermore, the ratios of  
So1P and Sa1P, relative to their nonphosphorylated forms, were markedly lower in the NOD-HET. So1P 
has been reported to promote T cell migration and retention in inflamed tissues (44). Reduced So1P would 
be expected to decrease T cell participation in promoting inflammation and is consistent with fewer CD4+ 
T cells and B cells in FKGK18-treated NOD islets (8). While little is known about Sa1P’s role in inflam-
mation, it has been reported to bind to the same receptors as So1P (45) and is thus expected to have similar 
function. Collectively, our analyses suggest that elevations in select lipids (i.e., LTs, EETs, So1P, Sa1P) may 
be given consideration as candidate biomarkers of  pre-T1D.
When the lipidome signature was assessed at T1D onset using plasma from NOD treated with PBS-T 
or FKGK18 (10-day regimen), elevations in select lipids were again identified in diabetic mice that were not 
evident in the nondiabetic mice. These included proinflammatory eicosanoids LTC4, 15-HETE, 5-HETE, 
and PGD2, as well as fatty acids AA and DHA. Furthermore, the ratio of  EET/DHET was lower in the 
diabetic group, relative to the nondiabetic groups. Abundance of  So1P was also higher in diabetic mice, 
compared with nondiabetic mice. Of  note, 10%–15% of  FKGK18-treated mice developed T1D, possibly 
related to higher susceptibility of  these mice to immune responses, and their lipidome was similar to vehi-
cle-treated diabetic NOD, strengthening the link between these iDLs and T1D development. These findings 
suggest that a proinflammatory iDL signature persists until T1D onset.
Another intriguing finding in our studies is that T1D development is accompanied by select elevations 
in iPLA2β-modulated antiinflammatory lipids, including resolvin D2 and its source, DHA; PGE1 and its 
source, DHGLA (46); and EPA, which is a source of  E-series resolvins (47), undetected in our analyses. 
During inflammation, generation of  pro- and antiinflammatory factors (i.e., cytokines and chemokines) 
can occur (48). This appears to be true with lipids, as well, and may reflect triggering of  compensatory 
mechanisms to affect resolution, which — if  not reinforced — leads to disease progression and frank 
diabetes. In T1D, it is likely that the impact of  proinflammatory lipids, if  not preempted, is far greater 
than that of  resolving lipids, to the extent that resolution of  inflammation fails and diabetes ensues (49). 
Indeed, Serhan’s group reported that resolvins were increased in sepsis patients with lower survival, which 
is contradictory to function (50). Thus, our findings suggest that resolving lipids may have therapeutic 
value if  given early by providing a break in the onset/progression of  inflammation.
Our identification of  changes in the abundances of  iDLs (i.e., DHETs, LTs, HETEs, So1P, PGE1) before 
T1D onset highlights the possibility that manipulating select lipid signaling during the prediabetes phase 
could be beneficial in preventing T1D development. Consistently, reduced T1D incidence has been report-
ed in NOD.Alox15–/– mice (38). While that study did not examine the lipidome, our findings suggest that 
production of  HETEs and LTs during T1D development is modulated by iPLA2β. They also raise the pos-
sibility that generating or repurposing FDA-approved drugs that inhibit sEH1 (TPPU), downregulate So1P 
(FTY720), interrupt LT and HETE signaling (receptor antagonists), or mimic the effects of  PGE1 (Alprosta-
dil) and SPMs (resolvins) could be beneficial in altering the course of  T1D onset and/or progression.
One potential drawback of  our studies may be that islet-resident MΦ, rather than peritoneal, are the 
key pool in the pathogenesis of  T1D. However, technical challenges prohibit thorough lipidomic analyses 
of  islet-resident MΦ as designed in our study. Elegant studies by the Unanue group revealed the presence 
of  only 10 resident MΦ/islet in the NOD (51, 52). This low number precludes the ability to perform cur-
rent lipidomics analyses that would require several thousand cells. Circulating monocyte-derived MΦ do 
comprise a significant source of  MΦ infiltrate within the islet (53, 54), and monocytes would be a feasible 
pool to harvest for examination. However, due to the fact that circulating monocytes require in situ MΦ 
differentiation to address function, we felt this method would potentially compromise optimal lipid analy-
ses as designed in our studies. Alternatively, peritoneal MΦ are easily retrievable from rodents and can be 
obtained in sufficiently large numbers from a single mouse to facilitate testing under multiple conditions. 
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As far back as 1994, Shimada et al. reported that administration of  peritoneal MΦ from overtly diabet-
ic NOD into young NOD accelerated insulitis and T1D incidence (55). Horio et al. demonstrated that 
peritoneal exudate that was rich in MΦ promoted ROS production in cultured islets, an effect that was 
not seen following exposure to T cells (56). Using an adoptive transfer protocol, Parsa et al. (15) isolated 
bone marrow–derived MΦ and treated them under conditions to generate MΦ of  M2 phenotype. NOD 
were then administered with either untreated or treated MΦ by the i.p. route. Whereas NOD administered 
untreated MΦ (or PBS alone) exhibited the expected T1D incidence (about 80% by 27 weeks of  age), the 
mice administered M2-MΦ were protected from developing T1D (only about 20%). Fluorescence and 
immunohistochemical analyses provided evidence of  accumulation of  the M2-MΦ within the pancreas 
and in close proximity to islets. Consistently, we find that adoptive transfer of  peritoneal MΦ isolated 
from NOD and NOD.iPLA2β
–/– (KO) mice reduced T1D incidence in NOD following i.p. administration 
of  peritoneal MΦ from MΦNOD-KO mice, relative to NOD administered MΦNOD. These findings support 
the ability of  peritoneal MΦ to migrate and infiltrate the pancreas/islets to promote affect and allow us 
to posit that the findings presented here can be representative of  MΦ that impact islets, leading to T1D.
Importantly, we report here a similar lipidome in the plasma of  children (<15 years of  age) that are at 
high risk for developing T1D. As per the Scientific Statement of  the Juvenile Diabetes Research Foundation 
(JDRF), Endocrine Society, and American Diabetes Association (ADA) (57), presymptomatic Aab++ are at 
44% and 70% risk for developing disease within 5 and 10 years, respectively, but with a lifetime risk approach-
ing 100% (58). Examination of  the lipidome of  euglycemic Aab–, Aab+, and Aab++ children revealed increases 
in the lipid signature (PGE2, PGD2, PGA2, 15-HETE, and LTE4) in the plasma of  euglycemic Aab
++, relative 
to nondiabetic Aab– and Aab+ children. Because these lipids were also among those identified as iDLs in the 
NOD controls during the prediabetic and T1D onset phases (Table 2), the lipidome identified in plasma from 
human children at high risk supports the possibility that these iDLs are linked to T1D onset in humans.
Increases in glucose concentrations promote iPLA2β-mediated hydrolysis of  arachidonic acid from 
β cell membrane glycerophospholipids (59, 60), and a recent in vitro study suggests that long-term expo-
sure to hyperglycemia sensitizes MΦ to cytokine stimulation (61). These findings raise the possibility that 
hyperglycemia drives the evolution of  altered MΦ lipid profile during T1D development. However, several 
lines of  studies suggest that this is not the case. Niu et al. (62) compared the impact of  hyperglycemia in 
both insulin-requiring diabetes (STZ) and type 2 (ob/ob) model on peritoneal MΦ and reported that MΦ 
from the STZ mice exhibited an increase in the proinflammatory status of  the MΦ. In contrast, they found 
that the peritoneal MΦ from ob/ob mice (T2D model) did not exhibit a proinflammatory phenotype, 
though they were moderately hyperglycemic. They concluded that increased proliferation and infiltration 
of  MΦ, but not hyperglycemia, was responsible for the inflammation associated with diabetes. Kanter 
et al. (63) assessed MΦ inflammatory phenotype using peritoneal MΦ and monocytes from 2 models 
of  rodent T1D (STZ and low-density lipoprotein receptor expressing a viral glycoprotein), which exhib-
ited hyperglycemia. They found that hyperglycemia increased both the basal and thioglycolate-elicited 
inflammatory phenotypes in peritoneal MΦ and that this was recapitulated in monocytes, suggesting that 
the inflammatory profile is similar between peritoneal MΦ and the circulating monocytes, further sup-
porting our study design. Importantly, they also noted a similar inflammatory phenotype in monocytes 
from human subjects with T1D, suggesting translatability of  the proinflammatory landscape. Further-
more, they reported that hyperglycemia promoted increases in peritoneal MΦ production of  PGE2, PGD2, 
15-HETE, and PGF2α (similar to our findings). While Ptgs2 and Ptges mRNA, which encode COX-2 and 
Table 2. Comparison of control NOD and human T1D lipidome
NOD T1D Human T1D
Prediabetic (8–14 weeks) Diabetes onset Aab++ subjects
PGE2  PGD2  PGE2, PGD2, PGA2  
15-HETE  15-HETE  15-HETE  
5-HETE  5-HETE  -
LTs  LTs  LTs  
So1P, Sa1P  So1P  -
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PTGS2, were induced by hyperglycemia, other enzymes that metabolize arachidonic acid (5-LO, 15-LO, 
or thromboxane A synthetase 1) were not in the M1-MΦ. These findings suggest that while hyperglycemia 
can impact lipid production from MΦ, it is limited to the COX-2 pathway.
To date, the effects of  hyperglycemia on MΦ iPLA2β have not been examined, to our knowledge. Here, 
we report that iPLA2β mRNA is significantly higher in MΦ from prediabetic (7–8 weeks of  age and nor-
moglycemic) NOD female, relative to age-matched C57 spontaneous diabetes–resistant mice. Furthermore, 
our data reveal increases in NOD MΦ production of  lipids before development of  hyperglycemia (i.e., 
between 4 and 8 weeks of  age). In fact, as the age of  diabetes nears (14 weeks), there are significant decreas-
es in those lipids. Additionally, several lipid species in the plasma of  normoglycemic human subjects pos-
itive for 2 Aabs (Aab++) are higher, relative to Aab– subjects. Taken together, these studies suggest that the 
lipid production by peritoneal MΦ we are reporting here is not driven by hyperglycemia. Nevertheless, 
as hyperglycemia can induce lipid production by a variety of  cells, including MΦ and β cells, it is likely a 
mechanism that may maintain high lipid levels after T1D onset.
In summary, we demonstrate that T1D development in the rodent is associated with a heightened 
inflammatory lipid landscape that evolves during the prediabetic phase. Such findings are also reflected in 
the plasma of  high-risk human subjects, suggesting that monitoring of  prediabetic human plasma lipidome 
will offer guidance for earlier intervention to better counter the T1D development. Importantly, our work 
identifies critical participation of  iPLA2β and select iDLs in T1D development, thus identifying potentially 
novel lipid-signaling candidates that can be targeted for therapeutics and, in conjunction with Aabs, serve 
as early biomarkers of  prediabetes. As such, early interventions to mitigate the inflammatory lipid profile 
may be beneficial in ameliorating T1D development.
Methods
Construction of  NOD.PLA2G6-null/Srvem mice
NOD breeding pairs were obtained from The Jackson Laboratory, and only female progeny, with 
expected 80% diabetes incidence, were used in experiments. NOD.iPLA2β
+/– (NOD-HET) were generated by 
breeding male NOD with iPLA2β-deficient (KO) female C57BL/6J (64), provided by John Turk (WUSM). 
The investigator-induced–null PLA2G6 allele was congenically introgressed into the NOD genome by first 
generating F1 hybrids from outcrosses of  C57BL/6J with NOD. These F1 hybrid females were backcrossed 
to NOD males, and the female progeny of  each successive generation were backcrossed to NOD males for 
a total of  10 generations. To eliminate contaminating chromosomal segments, genotyping was performed 
by PCR amplification of  94 polymorphic microsatellite primers (Invitrogen) covering all 19 autosomes for 
the first 6 generations, as described previously (65). By N6, mice were homozygous for NOD genome at all 
loci, except those in tight linkage with PLA2G6 on chromosome 15. From N6 until N10, genotyping was 
performed with markers on chromosome 15 to ensure transmission of  the nonfunctional PLA2G6 allele 
(65), allowing for mice with the smallest possible congenic segment to be bred. At generation N10, these 
marker-assisted or speed congenic mice were intercrossed to generate mice that were homozygous for the 
PLA2G6-null allele. These mice were then bred to generate NOD-WT (NOD) and NOD.iPLA2β
+/– (NOD-
HET) littermates used in subsequent studies.
NOD genotyping
Prior to experimentation, the mice were genotyped, as described (23), using the following primers (5′-3′) 
with expected product sizes: (sense/antisense: AGCTTCAGGATCTC-ATGCCCATC/CTCCGCTTCTC-
GTCCCTCATGGA, 1400 bp; MaExAS/Neo; GGGGCCTCAGACTGGGA-ATC/TCGCCTTCTATCG-
CCTTCTTGAC, 400 bp). Data from each genotype were compared against their corresponding WT litter-
mates. The mice were maintained with a standard light/dark cycle with ad libitum access to food and water.
Animal treatment, monitoring, and assessments
Blood glucose levels were measured weekly via tail vein blood draw (2 μL) with Breeze 2 Blood Glucose 
Monitoring System (Bayer HealthCare). Diabetes incidence was based on 2 consecutive blood glucose 
readings ≥ 275 mg/dL, at which time the mouse was euthanized. Experimental groups included the follow-
ing: (a) FKGK18, a reversible selective inhibitor of  iPLA2β (36) was administered via i.p. injection 3 times/
week to NOD at 20 mg/kg body weight starting at 10 days, 4 weeks, or 8 weeks of  age for up to 30 weeks, 
and mice receiving i.p. PBS + 5% Tween 80 (PBS-T) with the same dosing schedule were included as a 
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vehicle control group; (b) NOD were treated with PBS-T or FKGK18 from 10 days to 14 weeks of  age and 
then monitored for 30 weeks; (c) NOD and NOD-HET littermates were monitored for up to 30 weeks of  
age; and (d) NOD and NOD-HET mice were sacrificed at 4, 8, or 14 weeks of  age for lipidomics analyses. 
For insulin measurements, blood was collected at sacrifice (nonfasting) into BD Microtainer Tubes with 
serum separator and processed for ELISA (Mercodia Kit). Other assessments, as described (8), includ-
ed i.p. glucose tolerance test (IPGTT), islet infiltration, immunofluorescence analyses, β cell area, urine 
PGEM analyses, and CD4+ T cell assays. Pancreas section and islet images were captured on an Olympus 
IX81 microscope using cellSens Dimension software and analyzed using ImageJ software (NIH).
Isolation and activation of peritoneal MΦ
Mice were euthanized by CO2 inhalation and cervical dislocation. Peritoneal MΦ were obtained by filling 
the peritoneal cavity with cold 5 mL PBS containing 2% FBS, massaging gently, and withdrawing the 
cell-containing solution. Classical activation (IFN-γ + LPS) experiments were performed with freshly 
isolated and expanded peritoneal MΦ, as described (18). Briefly, MΦ were treated with 15 ng/mL recom-
binant IFN-γ (R&D Systems, 485-MI-100) for 8 hours in growth medium followed by addition of  10 ng/
mL ultrapure LPS (InvivoGen, tlrl-3pelps) and incubated for 16 hours at 37°C or IL-4 (R&D Systems, 
404-ML-010) for 16 hours in growth medium. Naive MΦ, which received no activation stimuli, were 
maintained in growth medium with no additional treatment. Subsequently, the media and MΦ were col-
lected for analyses of  eicosanoid and sphingolipid classes of  lipids, respectively.
MΦ mRNA target analyses
MΦ cultured in 60 mm nontissue culture–treated dishes were lysed in 1 mL of  TRIzol (Invitrogen, 15596-
026). Total RNA was prepared and purified using RNeasy Mini Kits (QIAGEN, 74104), and 1 μg RNA was 
converted to cDNA using the Superscript III first-strand synthesis system (Invitrogen, 18080-051), accord-
ing to manufacturer’s instructions. The cDNA was diluted 10-fold and used as template in conventional or 
quantitative PCR (qPCR). cDNA transcripts were amplified, as described (23), with the following forward/
reverse primers (5′-3′) at Tm: PLA2G6_qRT, GGCAGAAGTGGACACCCCAA/CATGGAGCTCAGGAT-
GAACGC, 60°C; msARG1_qRT, AGCACTGAG-GAAAGCTGGTC/CAGACCGTGGGTTCTTCACA, 
60°C; and 18S-qRT, CGCTTCCTTACCTGGTTGAT/ TCCCTCTCCGGAATCGAA, 60°C. qPCR was 
carried out using SYBR Select Mastermix (Invitrogen, 4472908) according to manufacturer’s instructions 
using 18S as an internal control. Relative gene expression levels were determined using the 2–ΔΔCt method.
Lipidomics analyses
Eicosanoids preparation. Eicosanoids were extracted using a modified extraction process, as previously 
described (66, 67). Plasma (150 μL) was combined with 850 μL of  liquid chromatography–mass spectrom-
etry H2O, followed by the addition of  an internal standard (IS) mixture. For media analysis, IS was added 
to media from cells (2 mL). Eicosanoid IS was comprised of  10% methanol (100 μL and 200 μL, respec-
tively, for plasma and media), glacial acetic acid (5 μL and 10 μL, respectively, for plasma and media), and 
internal standard (20 μL) containing the following deuterated eicosanoids (1.5 pmol/μL, 30 pmol total; all 
standards purchased from Cayman Chemicals): (d4) 6-keto PG F1α, (d4) PG F2α, (d4) PGE2, (d4) PG D2, 
(d8) 5-HETE, (d8) 12-HETE, (d8) 15-HETE, (d6) 20-HETE, (d11) 8,9 epoxyeicosatrienoic acid, (d8) 14,15 
epoxyeicosatrienoic acid, (d8) arachidonic acid, (d5) eicosapentaenoic acid, (d5) docosahexaenoic acid, (d4) 
PG A2, (d4) LT B4, (d4) LT C4, (d4) LTD4, (d4) LTE4, (d5) 5(S),6(R)-lipoxin A4, (d11) 5-iPF2α -VI, (d4) 8-iso 
PG F2α, (d11) (±) 14,15-DHET, (d11) (±) 8,9-DHET, (d11) (±) 11,12-DHET, (d4) PG E1, (d4) thromboxane 
B2, (d6) dihomo-γ-linoleic acid, (d5) resolvin D2, (d5) resolvin D1, (d5) maresin 2, and (d5) resolvin D3. Sam-
ples and vial rinses (5% MeOH; 2 mL) were applied to Strata-X SPE columns (Phenomenex), previously 
washed with methanol (2 mL) and then dH2O (2 mL). Eicosanoids eluted with isopropanol (2 mL) were 
dried in vacuuo and reconstituted in EtOH/dH2O (50:50; 100 μL) before analysis.
Sphingolipids preparation. Cell pellets and plasma (50 μL) were extracted using a modified Bligh Dyer 
extraction, as previously described (67–69). Samples were spiked with 250 pmol of  C1P, SM, CM, and mono-
hexosyl CM (d18:1/12:0 species), and sphingansine, sphinganine, sphingasine-1–phosphate, sphinganine-1–
phosphate (d17:0 sphinganine/d17:1 sphingosine) as internal standard (Avanti Polar Lipids). Among the 
sphingolipids analyzed were CMs (C14:0, C16:0, C18:1, C18:0, C20:0, C22:0, C24:1, C24:0, C26:1, C26:0), 
monohexyl CMs (C14:0, C16:0, C18:1, C18:0, C20:0, C22:0, C24:1, C24:0, C26:1, C26:0), SMs (C14:0, 
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C16:0, C18:1, C18:0, C20:0, C22:0, C24:1, C24:0, C26:1, C26:0), CM-1-phosphates (C14:0, C16:0, C18:1, 
C18:0, C20:0, C22:0, C24:1, C24:0, C26:1, C26:0), 18:1-sphingosine (C18:1-So) C18:1–sphingosine-1–phos-
phate (C18:1-So1P), and C18:1-sphinganine (C18:1-Sa) and C18:1–sphinganine-1–phosphate (C18:1-Sa1P).
Analysis of  sphingolipids, eicosanoids, and fatty acids by ultra performance liquid chromatography–electrospray 
ionization–tandem mass spectrometry. Lipids in the samples were separated using 2 Shimadzu Nexera X2 
LC-30AD pumps coupled to a SIL-30AC auto injector, coupled to a DGU-20A5R degassing unit. Sphin-
golipids, eicosanoids, and fatty acids were analyzed via mass spectrometry using an AB Sciex Triple Quad 
5500 Mass Spectrometer. MRM transitions with corresponding declustering potentials, collision energies, 
entrance potentials, and collision cell exit potentials are shown in Supplemental Tables 1 and 2.
MΦ adoptive transfer. Peritoneal MΦ were obtained from 8-week-old female NOD and NOD.
iPLA2β
–/– (NOD-KO) mice. The MΦ (2.75 × 106) were administered i.p. to 8-week-old female NOD, 
and diabetes incidence was recorded through weekly blood glucose monitoring.
Human lipidome. Study subjects were recruited through Children’s Hospital of  Wisconsin, and diagno-
sis of  T1D was defined per World Health Organization criteria (70). All RO T1D subjects were positive 
for > 1 Aab and were drawn from subjects with histories of  good glycemic control (HbA1c, 7.53% ± 
0.28%). Subjects within the 3 nondiabetic (normoglycemic) sibling groups (Aab–, Aab+, Aab++) were free 
of  known infection at blood collection. Measurements of  Aabs targeting GAD, IA2, insulin, and zinc 
transporter 8 (ZnT8) were as described (71).
Statistics
Significant difference in T1D incidence was determined by the Mantel-Cox test. For all other analyses, 
P values were determined using either 2-tailed Student’s t test (for analysis of  2 groups), multivariate 
analysis of  variance (for analyses testing more than 1 outcome), time-course ANOVA (for temporal lipid 
analysis), or 1- or 2-way ANOVA (for tests including more than 1 sample group). To assess the relation-
ship between selected eicosanoids in human plasma, the data were subjected to a linear regression analysis 
(Pearson, Kendall, and Spearman rank-order correlation) using only the Aab–, Aab+, and Aab++ values, 
under the rationale that RO subjects are already diabetic and usually controlled with therapeutics. Statisti-
cal programs used were either SPSS or R; P < 0.05 was taken to indicate significant differences.
Study approval
All animal experiments were conducted according to approved IACUC guidelines at UAB. Human 
study participants were recruited through the Children’s Hospital of  Wisconsin, and samples were col-
lected as described (72). IRB approval (CHW IRB 01–15) was granted for all analyses, and informed 
consent/assent was obtained from subjects or their parents/legal guardians. Acquisition and analyses 
of  samples was approved by UAB (IRB-100813004).
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